SCHEDULE 13G/A: 12 West Capital Management LP Discloses 8.2% Passive Stake in Maravai LifeSciences Holdings, Inc.

Investment firm 12 West Capital Management LP and Joel Ramin have filed an amended Schedule 13G, reporting a shared beneficial ownership of 8.2% of Maravai LifeSciences Holdings, Inc.'s Class A Common Stock as of December 31, 2024.

Summary

• 12 West Capital Management LP and Joel Ramin collectively reported beneficial ownership of 11,591,335 shares of Maravai LifeSciences Holdings, Inc. Class A Common Stock.
• This ownership represents 8.2% of the total Class A Common Stock outstanding.
• The percentage is calculated based on 141,843,505 shares of Class A Common Stock outstanding as of November 7, 2024, as reported in Maravai LifeSciences' Quarterly Report on Form 10-Q for the period ended September 30, 2024.
• Both 12 West Capital Management LP and Joel Ramin hold shared voting power and shared dispositive power over all 11,591,335 shares.
• The filing is an Amendment No. 3 to a previously filed Schedule 13G, indicating an update to an existing beneficial ownership disclosure.
• The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: Neutral, as this is a routine disclosure of passive beneficial ownership and does not contain performance or strategic updates from the issuer.

Future Outlook

This document, a Schedule 13G filing, is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding the issuer's future outlook or performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a routine disclosure of a significant passive ownership stake by an investment firm in a life sciences company. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant passive ownership stake held by an investment firm, which can influence market perception and liquidity.

Key Dates

Keywords

Maravai LifeSciences Holdings Inc, 12 West Capital Management LP, Joel Ramin, Schedule 13G, Beneficial Ownership, Class A Common Stock, Investment Management, Life Sciences, Biotechnology